Arcus Biosciences (RCUS) Cash from Investing Activities (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.64% |
| Dec 31, 2025 | -330.38% |
| Sep 30, 2025 | -42.34% |
| Jun 30, 2025 | 328.13% |
| Mar 31, 2025 | -37.25% |
| Dec 31, 2024 | 275.86% |
| Sep 30, 2024 | -146.03% |
| Jun 30, 2024 | 137.28% |
| Mar 31, 2024 | -703.57% |
| Dec 31, 2023 | 154.55% |
| Sep 30, 2023 | -57.69% |
| Jun 30, 2023 | -79.84% |
| Mar 31, 2023 | 174.47% |
| Dec 31, 2022 | 104.35% |
| Sep 30, 2022 | 110.70% |
| Jun 30, 2022 | 19.78% |
| Mar 31, 2022 | -1,526.90% |
| Dec 31, 2021 | 121.20% |
| Sep 30, 2021 | -3,050.75% |
| Jun 30, 2021 | -95.22% |
| Mar 31, 2021 | 46,095.59% |
| Dec 31, 2020 | 100.04% |
| Sep 30, 2020 | -344.59% |
| Jun 30, 2020 | -317.38% |
| Mar 31, 2020 | 430.93% |
| Dec 31, 2019 | -139.86% |
| Sep 30, 2019 | 13.84% |
| Jun 30, 2019 | 86.80% |
| Mar 31, 2019 | 468.66% |
| Dec 31, 2018 | 103.01% |
| Sep 30, 2018 | -416.88% |
| Jun 30, 2018 | 2.23% |
| Mar 31, 2018 | 60.80% |
| Dec 31, 2017 | -430.42% |
| Sep 30, 2017 | 492.57% |
| Jun 30, 2017 | 80.34% |